162 related articles for article (PubMed ID: 2965116)
1. Technetium-99m labeled renal function and imaging agents: II. Clinical evaluation of 99mTc MAG3 (99mTc mercaptoacetylglycylglycylglycine).
Bubeck B; Brandau W; Steinbächer M; Reinbold F; Dreikorn K; Eisenhut M; Georgi P
Int J Rad Appl Instrum B; 1988; 15(1):109-18. PubMed ID: 2965116
[TBL] [Abstract][Full Text] [Related]
2. Comparison of technetium-99m MAG3 kit with HPLC-purified technetium-99m MAG3 and OIH in rats.
Coveney JR; Robbins MS
J Nucl Med; 1987 Dec; 28(12):1881-7. PubMed ID: 2960790
[TBL] [Abstract][Full Text] [Related]
3. Comparison of iodine-131 OIH and technetium-99m MAG3 renal imaging in volunteers.
Taylor A; Eshima D; Fritzberg AR; Christian PE; Kasina S
J Nucl Med; 1986 Jun; 27(6):795-803. PubMed ID: 2940350
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of technetium-99m-MAG3 in humans.
Bubeck B; Brandau W; Weber E; Kälble T; Parekh N; Georgi P
J Nucl Med; 1990 Aug; 31(8):1285-93. PubMed ID: 2143528
[TBL] [Abstract][Full Text] [Related]
5. Technetium-99m (99mTc) mercaptoacetyltriglycine: update on the new 99mTc renal tubular function agent.
Eshima D; Taylor A
Semin Nucl Med; 1992 Apr; 22(2):61-73. PubMed ID: 1534184
[TBL] [Abstract][Full Text] [Related]
6. Effects of altered physiologic states on clearance and biodistribution of technetium-99m MAG3, iodine-131 OIH, and iodine-125 iothalamate.
Taylor A; Eshima D
J Nucl Med; 1988 May; 29(5):669-75. PubMed ID: 2967354
[TBL] [Abstract][Full Text] [Related]
7. Technetium-99m labeled renal function and imaging agents: I. Clinical evaluation of 99mTc CO2-DADS-A (99mTc N,N'-bis-(mercaptoacetyl)-2,3-diaminopropanoate).
Bubeck B; Brandau W; Reinbold F; Dreikorn K; Steinbächer M; Eisenhut M; Georgi P
Int J Rad Appl Instrum B; 1988; 15(1):99-108. PubMed ID: 3127358
[TBL] [Abstract][Full Text] [Related]
8. [Parametric representation of kidney function using 99mTc-mercaptoacetyltriglycine (MAG3)].
Szabó Z; Kutkuhn B; Georgescu G; Mecklenbeck W; Suatmadji A; Vosberg H
Nuklearmedizin; 1989 Jun; 28(3):73-83. PubMed ID: 2525703
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and biological evaluation of technetium-99m MAG3 as a hippuran replacement.
Fritzberg AR; Kasina S; Eshima D; Johnson DL
J Nucl Med; 1986 Jan; 27(1):111-6. PubMed ID: 2934521
[TBL] [Abstract][Full Text] [Related]
10. 99mTc renal tubular function agents: current status.
Eshima D; Fritzberg AR; Taylor A
Semin Nucl Med; 1990 Jan; 20(1):28-40. PubMed ID: 2136959
[TBL] [Abstract][Full Text] [Related]
11. Technetium-99m labeled renal function and imaging agents: III. Synthesis of 99mTc-MAG3 and biodistribution of by-products.
Brandau W; Bubeck B; Eisenhut M; Taylor DM
Int J Rad Appl Instrum A; 1988; 39(2):121-9. PubMed ID: 2833469
[TBL] [Abstract][Full Text] [Related]
12. 99mTc-MAG3, a new renal imaging agent: preliminary results in patients.
Taylor A; Eshima D; Alazraki N
Eur J Nucl Med; 1987; 12(10):510-4. PubMed ID: 2952506
[TBL] [Abstract][Full Text] [Related]
13. 99mTc-MAG3: dynamic studies in patients with renal disease.
Schaap GH; Alferink TH; de Jong RB; Oe PL; Roos JC; Donker AJ
Eur J Nucl Med; 1988; 14(1):28-31. PubMed ID: 2968259
[TBL] [Abstract][Full Text] [Related]
14. Clinical comparison of I-131 orthoiodohippurate and the kit formulation of Tc-99m mercaptoacetyltriglycine.
Taylor A; Ziffer JA; Steves A; Eshima D; Delaney VB; Welchel JD
Radiology; 1989 Mar; 170(3 Pt 1):721-5. PubMed ID: 2521734
[TBL] [Abstract][Full Text] [Related]
15. Clinical comparison of technetium-99m-EC, technetium-99m-MAG3 and iodine-131-OIH in renal disorders.
Kabasakal L; Turoğlu HT; Onsel C; Ozker K; Uslu I; Atay S; Cansiz T; Sönmezoğlu K; Altiok E; Isitman AT
J Nucl Med; 1995 Feb; 36(2):224-8. PubMed ID: 7830118
[TBL] [Abstract][Full Text] [Related]
16. Comparison of 99mTc-mercaptoacetyltriglycine and [131I]-o-iodohippurate elimination in perfused rat kidney.
Trejtnar F; Laznicek M; Laznickova A
Nucl Med Biol; 2003 Jan; 30(1):45-9. PubMed ID: 12493542
[TBL] [Abstract][Full Text] [Related]
17. A comparative study of renal scintigraphy and clearance with technetium-99m-MAG3 and iodine-123-hippurate in patients with renal disorders.
Müller-Suur R; Bois-Svensson I; Mesko L
J Nucl Med; 1990 Nov; 31(11):1811-7. PubMed ID: 2146371
[TBL] [Abstract][Full Text] [Related]
18. Renal and extrarenal clearance of 99mTc-MAG3: a comparison with 125I-OIH and 51Cr-EDTA in patients representing all levels of glomerular filtration rate.
Rehling M; Nielsen BV; Pedersen EB; Nielsen LE; Hansen HE; Bacher T
Eur J Nucl Med; 1995 Dec; 22(12):1379-84. PubMed ID: 8586082
[TBL] [Abstract][Full Text] [Related]
19. Technetium-99m MAG3, a comparison with iodine-123 and iodine-131 orthoiodohippurate, in patients with renal disorders.
Jafri RA; Britton KE; Nimmon CC; Solanki K; Al-Nahhas A; Bomanji J; Fettich J; Hawkins LA
J Nucl Med; 1988 Feb; 29(2):147-58. PubMed ID: 2964516
[TBL] [Abstract][Full Text] [Related]
20. Effect of protein binding on renal extraction of 131I-OIH and 99mTc-labeled tubular agents.
Eshima D; Eshima L; Hansen L; Lipowska M; Marzilli LG; Taylor A
J Nucl Med; 2000 Dec; 41(12):2077-82. PubMed ID: 11138695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
